Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL880589 | 0.96 | — | — | |
| Hydrochloric Acid SCHEMBL68106 | 0.93 | — | — | |
| Sulfuric Acid SCHEMBL11125847 | 0.82 | KDM4E (0.37) | — | |
| Nitric Acid SCHEMBL28646165 | 0.78 | CA5A (0.40) | — | |
| SCHEMBL2246543 | 0.74 | — | — | |
| SCHEMBL20857227 | 0.74 | KDM4E (0.60) | — | |
| SCHEMBL3071851 | 0.74 | KDM4E (0.60) | — | |
| SCHEMBL28386962 | 0.74 | CA12 (0.33) | — | |
| SCHEMBL28996859 | 0.72 | KDM4E (0.31) | — | |
| SCHEMBL152642 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 539 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11717481-B2 | Reduction of flake-like aggregation in nanoparticulate active agent compositions | ALKERMES PHARMA IRELAND LIMITED (IE) | 2023-08-08 | — | — | US | claimed |
| US-20220211626-A1 | REDUCTION OF FLAKE-LIKE AGGREGATION IN NANOPARTICULATE ACTIVE AGENT COMPOSITIONS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2022-07-07 | — | — | US | claimed |
| US-11253478-B2 | Reduction of flake-like aggregation in nanoparticulate active agent compositions | ALKERMES PHARMA IRELAND LIMITED (IE) | 2022-02-22 | — | — | US | claimed |
| CN-109570485-B | Method for detecting pigment with negative charges | 安徽中科赛飞尔科技有限公司 | 2021-10-01 | — | — | CN | claimed |
| EP-3755148-A1 | NANOSUSPENSIONS OF SALSALATE AND METHODS OF USING THE SAME | RHNanoPharma (US) | 2020-12-30 | — | — | EP | claimed |
| US-20200390737-A1 | NANOSUSPENSIONS OF SALSALATE AND METHODS OF USING THE SAME | RHNANOPHARMA (US) | 2020-12-17 | — | — | US | claimed |
| WO-2020065541-A1 | MICROEMULSIONS AND METHODS OF USE | MOROCCANOIL ISRAEL, LTD. (IL) | 2020-04-02 | — | — | WO | claimed |
| WO-2019165240-A1 | NANOSUSPENSIONS OF SALSALATE AND METHODS OF USING THE SAME | RHNANOPHARMA (US) | 2019-08-29 | — | — | WO | claimed |
| US-20180250229-A1 | REDUCTION OF FLAKE-LIKE AGGREGATION IN NANOPARTICULATE ACTIVE AGENT COMPOSITIONS | ALKERMES PHARMA IRELAND LIMITED (IE) | 2018-09-06 | — | — | US | claimed |
| US-9974746-B2 | Reduction of flake-like aggregation in nanoparticulate active agent compositions | ALKERMES PHARMA IRELAND LIMITED (IE) | 2018-05-22 | — | — | US | claimed |
| WO-2003080024-A2 | NANOPARTICULATE COMPOSITIONS OF MAP KINASE INHIBITORS | ELAN PHARMA INTERNATIONAL, LTD. (IE) | 2003-10-02 | — | — | WO | claimed |
| WO-2003080027-A1 | NANOPARTICULATE COMPOSITIONS OF ANGIOGENESIS INHIBITORS | ELAN PHARMA INTERNATIONAL, LTD. (IE) | 2003-10-02 | — | — | WO | claimed |
| WO-2003080023-A2 | FAST DISSOLVING DOSAGE FORMS HAVING REDUCED FRIABILITY | ELAN PHARMA INTERNATIONAL LIMITED (IE) | 2003-10-02 | — | — | WO | claimed |
| US-20030185869-A1 | Having lysozyme adsorbed onto or associated with the surface of an active agent | ELAN PHARMA INTERNATIONAL LTD. | 2003-10-02 | — | — | US | claimed |
| US-20030181411-A1 | Contacting and adsorbing an insoluble enzyme inhibitor with a surface stabilizer | ELAN PHARMA INTERNATIONAL LTD. | 2003-09-25 | — | — | US | claimed |
| WO-2003066021-A2 | DRUG NANOPARTICLES WITH LYSOZYME SURFACE STABILISER | ELAN PHARMA INTERNATIONAL, LTD. (IE) | 2003-08-14 | — | — | WO | claimed |
| US-20030137067-A1 | Compositions having a combination of immediate release and controlled release characteristics | ELAN PHARMA INTERNATIONAL LTD. | 2003-07-24 | — | — | US | claimed |
| US-20030095928-A1 | Nanoparticulate insulin | ELAN PHARMA INTERNATIONAL LIMITED | 2003-05-22 | — | — | US | claimed |
| WO-2003030872-A2 | COMPOSITIONS HAVING A COMBINATION OF PARTICLES FOR IMMEDIATE RELEASE AND FOR CONTROLLED RELEASE | ELAN PHARMA INTERNATIONAL LTD. (IE) | 2003-04-17 | — | — | WO | claimed |
| WO-2003024425-A1 | NANOPARTICULATE INSULIN FORMULATIONS | ELAN PHARMA INTERNATIONAL, LTD. (IE) | 2003-03-27 | — | — | WO | claimed |